Research progress and value of albumin-related inflammatory markers in the prognosis of non-small cell lung cancer: a review of clinical evidence

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Tan Z, Xue H, Sun Y, et al. The role of tumor inflammatory microenvironment in lung cancer. Front Pharmacol. 2021;12:688625.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. Nat Immunol. 2017;18(8):843–850.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Karube Y, Matsumura Y, et al. Inflammatory risk factors for early recurrence of Non-Small cell lung cancer within one year following curative resection. World J Surg. 2020;44(10):3510–3521.
   PubMed Web of Science ®Google Scholar
• Brown D, Zingone A, Yu Y, et al. Relationship between circulating inflammation proteins and lung cancer diagnosis in the national lung screening trial. Cancer Epidemiol Biomarkers Prev. 2019;28(1):110–118.
   PubMed Web of Science ®Google Scholar
• Gomes M, Teixeira AL, Coelho A, et al. The role of inflammation in lung cancer. Adv Exp Med Biol. 2014;816:1–23.
   PubMed Web of Science ®Google Scholar
• Conway EM, Pikor LA, Kung SH, et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193(2):116–130.
   PubMed Web of Science ®Google Scholar
• Lagiou P, Trichopoulos D. Inflammatory biomarkers and risk of lung cancer. J Natl Cancer Inst. 2011;103(14):1073–1075.
   PubMedGoogle Scholar
• Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Semin Arthritis Rheum. 2021;51(1):219–229.
   PubMed Web of Science ®Google Scholar
• Polanski J, Chabowski M, Swiatoniowska-Lonc N, et al. Relationship between nutritional status and clinical outcome in patients treated for lung cancer. Nutrients. 2021;13(10):3332.
   PubMed Web of Science ®Google Scholar
• Wei Q, Fang W, Chen X, et al. Establishment and validation of a mathematical diagnosis model to distinguish benign pulmonary nodules from early non-small cell lung cancer in chinese people. Transl Lung Cancer Res. 2020;9(5):1843–1852.
   PubMed Web of Science ®Google Scholar
• Stares M, Swan A, Cumming K, et al. Hypoalbuminaemia as a prognostic biomarker of First-Line treatment resistance in metastatic non-small cell lung cancer. Front Nutr. 2021;8:734735.
   PubMed Web of Science ®Google Scholar
• Kaymak Cerkesli ZA, Ozkan EE, Ozseven A. The esophageal dose-volume parameters for predicting grade I-II acute esophagitis correlated with weight loss and serum albumin decrease in lung cancer radiotherapy. J Cancer Res Ther. 2021;17(1):94–98.
   PubMed Web of Science ®Google Scholar
• Takada K, Takamori S, Yoneshima Y, et al. Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy. Lung Cancer. 2020;145:18–26.
   PubMed Web of Science ®Google Scholar
• Fairclough E, Cairns E, Hamilton J, et al. Evaluation of a modified early warning system for acute medical admissions and comparison with C-reactive protein/albumin ratio as a predictor of patient outcome. Clin Med (Lond). 2009;9(1):30–33.
   PubMed Web of Science ®Google Scholar
• Zhou T, Zhan J, Hong S, et al. Ratio of C-Reactive protein/albumin is an inflammatory prognostic score for predicting overall survival of patients with small-cell lung cancer. Sci Rep. 2015;5:10481.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Yamasaki N, Tsuchiya T, et al. Ratio of C-reactive protein to albumin is a prognostic factor for operable non-small-cell lung cancer in elderly patients. Surg Today. 2017;47(7):836–843.
   PubMed Web of Science ®Google Scholar
• Forrest LM, McMillan DC, McArdle CS, et al. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–1030.
   PubMed Web of Science ®Google Scholar
• Forrest LM, McMillan DC, McArdle CS, et al. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704–1706.
   PubMed Web of Science ®Google Scholar
• Minami S, Ihara S, Kim SH, et al. Lymphocyte to monocyte ratio and modified glasgow prognostic score predict prognosis of lung adenocarcinoma without driver mutation. World J Oncol. 2018;9(1):13–20.
   PubMedGoogle Scholar
• McMillan DC, Crozier JE, Canna K, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for Colon and rectal cancer. Int J Colorectal Dis. 2007;22(8):881–886.
   PubMed Web of Science ®Google Scholar
• O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37(1):36–40.
   PubMed Web of Science ®Google Scholar
• Osugi J, Muto S, Matsumura Y, et al. Prognostic impact of the high-sensitivity modified glasgow prognostic score in patients with resectable non-small cell lung cancer. J Cancer Res Ther. 2016;12(2):945–951.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Murakawa T, Shinozaki T, et al. Significance of the glasgow prognostic score as a prognostic indicator for lung cancer surgery. Interact Cardiovasc Thorac Surg. 2015;21(5):637–643.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Okamoto T. ASO author reflections: the C-Reactive protein (CRP)-albumin ratio may be useful as the most prognostic index among the immuno-nutritional parameters using CRP and albumin for resected NSCLC. Ann Surg Oncol. 2021;28(6):3055–3056.
   PubMed Web of Science ®Google Scholar
• Tomita M, Ayabe T, Chosa E, et al. Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer. Anticancer Res. 2014;34(6):3137–3140.
   PubMed Web of Science ®Google Scholar
• Jiang AG, Lu HY. The glasgow prognostic score as a prognostic factor in patients with advanced non-small cell lung cancer treated with cisplatin-based first-line chemotherapy. J Chemother. 2015;27(1):35–39.
   PubMed Web of Science ®Google Scholar
• Zhang CL, Fan K, Gao MQ, et al. Prognostic value of glasgow prognostic score in non-small cell lung cancer: a systematic review and Meta-Analysis. Pathol Oncol Res. 2022;28:1610109.
   PubMed Web of Science ®Google Scholar
• McMillan DC, Watson WS, O'Gorman P, et al. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer. 2001;39(2):210–213.
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Safi S, Muley T, et al. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. Lung Cancer. 2017;114:62–67.
   PubMed Web of Science ®Google Scholar
• Zhang F, Ying L, Jin J, et al. The C-reactive protein/albumin ratio predicts long-term outcomes of patients with operable non-small cell lung cancer. Oncotarget. 2017;8(5):8835–8842.
   PubMedGoogle Scholar
• Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer. Asia Pac J Clin Oncol. 2018;14(6):402–409.
   PubMed Web of Science ®Google Scholar
• Yang JR, Xu JY, Chen GC, et al. Post-diagnostic C-reactive protein and albumin predict survival in chinese patients with non-small cell lung cancer: a prospective cohort study. Sci Rep. 2019;9(1):8143.
   PubMedGoogle Scholar
• Karahan I, Yalcin S. Is C-Reactive protein/albumin ratio of Advanced-Stage non-small cell lung cancer patients able to predict mortality in the admission for palliative care? Indian J Palliat Care. 2020;26(3):365–368.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Takamori S, Haratake N, et al. Identification of the best prognostic marker among immunonutritional parameters using serum C-Reactive protein and albumin in Non-Small cell lung cancer. Ann Surg Oncol. 2021;28(6):3046-3054.
   Web of Science ®Google Scholar
• Araki T, Tateishi K, Sonehara K, et al. Clinical utility of the C-reactive protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab. Thorac Cancer. 2021; 12(5):603-612.
   Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet. 2001;357(9255):539–545.
   PubMed Web of Science ®Google Scholar
• Dupre A, Malik HZ. Inflammation and cancer: what a surgical oncologist should know. Eur J Surg Oncol. 2018;44(5):566–570.
   PubMed Web of Science ®Google Scholar
• Zahorec R. Ratio of neutrophil to lymphocyte counts–rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy. 2001;102(1):5–14.
   PubMedGoogle Scholar
• Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther. 2018;11:955–965.
   PubMed Web of Science ®Google Scholar
• Hong YF, Chen ZH, Wei L, et al. Identification of the prognostic value of lymphocyte-to-monocyte ratio in patients with HBV-associated advanced hepatocellular carcinoma. Oncol Lett. 2017;14(2):2089–2096.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang W, Zhang X, et al. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer. Cancer Manag Res. 2018;10:5411–5422.
   PubMed Web of Science ®Google Scholar
• Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 2015;26(4):286–292.
   PubMed Web of Science ®Google Scholar
• Rossaint J, Margraf A, Zarbock A. Role of platelets in leukocyte recruitment and resolution of inflammation. Front Immunol. 2018;9:2712.
   PubMed Web of Science ®Google Scholar
• Kos FT, Hocazade C, Kos M, et al. Assessment of prognostic value of "neutrophil to lymphocyte ratio" and "prognostic nutritional index" as a sytemic inflammatory marker in non-small cell lung cancer. Asian Pac J Cancer Prev. 2015;16(9):3997–4002.
   PubMedGoogle Scholar
• Migita K, Takayama T, Saeki K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol. 2013;20(8):2647–2654.
   PubMed Web of Science ®Google Scholar
• Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158.
   PubMed Web of Science ®Google Scholar
• Weng J, Huang J, Yu W, et al. Combination of albumin concentration and neutrophil-to-lymphocyte ratio for predicting overall survival of patients with non-small cell lung cancer. J Thorac Dis. 2021;13(9):5508–5516.
   PubMed Web of Science ®Google Scholar
• Sun WW, Hu JA, Niu WQ, et al. Significance of NLDA, the commixed index of inflammation, immune responses, hemostasis, and nutrition, for predicting metastatic non-small cell lung cancer prognosis and metastases. Oncotarget. 2017;8(47):81978–81993.
   PubMedGoogle Scholar
• Sun H, Hu P, Shen H, et al. Albumin and neutrophil combined prognostic grade as a new prognostic factor in Non-Small cell lung cancer: results from a large consecutive cohort. PLoS One. 2015;10(12):e0144663.
   PubMed Web of Science ®Google Scholar
• Zhai B, Chen J, Wu J, et al. Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery. Ann Transl Med. 2021;9(12):976.
   PubMed Web of Science ®Google Scholar
• Mori S, Usami N, Fukumoto K, et al. The significance of the prognostic nutritional index in patients with completely resected Non-Small cell lung cancer. PLoS One. 2015;10(9):e0136897.
   PubMed Web of Science ®Google Scholar
• Shoji F, Miura N, Matsubara T, et al. Prognostic significance of immune-nutritional parameters for surgically resected elderly lung cancer patients: a multicentre retrospective study. Interact Cardiovasc Thorac Surg. 2018;26(3):389–394.
   PubMed Web of Science ®Google Scholar
• Qiu C, Qu X, Shen H, et al. Evaluation of prognostic nutritional index in patients undergoing radical surgery with nonsmall cell lung cancer. Nutr Cancer. 2015;67(5):741–747.
   PubMed Web of Science ®Google Scholar
• Okada S, Shimada J, Kato D, et al. Clinical significance of prognostic nutritional index after surgical treatment in lung cancer. Ann Thorac Surg. 2017;104(1):296–302.
   PubMed Web of Science ®Google Scholar
• Okada S, Shimada J, Teramukai S, et al. Risk stratification according to the prognostic nutritional index for predicting postoperative complications after lung cancer surgery. Ann Surg Oncol. 2018;25(5):1254–1261.
   PubMed Web of Science ®Google Scholar
• Park S, Ahn HJ, Yang M, et al. The prognostic nutritional index and postoperative complications after curative lung cancer resection: a retrospective cohort study. J Thorac Cardiovasc Surg. 2020;160(1):276–285 e1.
   PubMed Web of Science ®Google Scholar
• Matsubara T, Hirai F, Yamaguchi M, et al. Immunonutritional indices in non-small-cell lung cancer patients receiving adjuvant platinum-based chemotherapy. Anticancer Res. 2021;41(10):5157–5163.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Okita R, Saisho S, et al. Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer. Ther Clin Risk Manag. 2015;11:1555–1561.
   PubMed Web of Science ®Google Scholar
• Park S, Park S, Lee SH, et al. Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations. Korean J Intern Med. 2016;31(6):1140–1149.
   PubMed Web of Science ®Google Scholar
• Nakao M, Muramatsu H, Kagawa Y, et al. Immunological status may predict response to nivolumab in non-small cell lung cancer without driver mutations. Anticancer Res. 2017;37(7):3781–3786.
   PubMed Web of Science ®Google Scholar
• Shoji F, Takeoka H, Kozuma Y, et al. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 2019;136:45–51.
   PubMed Web of Science ®Google Scholar
• Ozkan EE, Kaymak Cerkesli ZA, Erdogan M. Predictive value of immune-inflammation indices in metabolic response and outcome after curative radiotherapy in patients with non-small cell lung cancer. Clin Respir J. 2020;14(9):849–856.
   PubMed Web of Science ®Google Scholar
• Peng L, Wang Y, Liu F, et al. Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020;69(9):1813–1822.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu Y, Mi X, et al. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics. Ann Palliat Med. 2020;9(3):967–978.
   PubMed Web of Science ®Google Scholar
• Kuroda H, Takahashi Y, Shirai S, et al. Survival benefit of immune checkpoint inhibitor monotherapy in patients with non-small cell lung cancer recurrence after completely pulmonary resection. Ann Transl Med. 2021;9(15):1225.
   PubMed Web of Science ®Google Scholar
• Liu N, Jiang A, Zheng X, et al. Prognostic nutritional index identifies risk of early progression and survival outcomes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors. J Cancer. 2021;12(10):2960–2967.
   PubMed Web of Science ®Google Scholar
• Takeda T, Yamada T, Tanimura K, et al. Prognostic markers of survival among japanese patients with anaplastic lymphoma Kinase-Positive Non-Small-Cell lung cancer receiving First-Line alectinib. Diagnostics (Basel). 2021;11(12):2170.
   PubMedGoogle Scholar
• Hayasaka K, Shiono S, Suzuki K, et al. Postoperative prognostic nutritional index as a prognostic factor after non-small cell lung cancer surgery. Gen Thorac Cardiovasc Surg. 2020;68(10):1163–1171.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Sowa T, Tokumasu H, et al. Comparison of three nutritional scoring systems for outcomes after complete resection of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021;162(4):1257–1268 e3.
   PubMed Web of Science ®Google Scholar
• Xu S, Cao S, Geng J, et al. High prognostic nutritional index (PNI) as a positive prognostic indicator for non-small cell lung cancer patients with bone metastasis. Clin Respir J. 2021;15(2):225–231.
   PubMed Web of Science ®Google Scholar
• Li XL, Yao ZH, Wan YY, et al. Prognostic impact of prognostic nutritional index in advanced (stage IIIB/IV) non-small cell lung cancer patients. Neoplasma. 2019;66(6):971–977.
   PubMed Web of Science ®Google Scholar
• Seo Y, Eo W, Kim S, et al. Can nutritional status predict overall survival in patients with advanced Non-Small cell lung cancer? Nutr Cancer. 2019;71(7):1108–1117.
   PubMed Web of Science ®Google Scholar
• Bozkaya Y, Kostek O, Sakin A, et al. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy? Support Care Cancer. 2020;28(5):2273–2282.
   PubMed Web of Science ®Google Scholar
• Ozdemir Y, Topkan E, Mertsoylu H, et al. Low prognostic nutritional index predicts poor clinical outcomes in patients with stage IIIB non-small-cell lung carcinoma undergoing chemoradiotherapy. Cancer Manag Res. 2020;12:1959–1967.
   PubMed Web of Science ®Google Scholar
• Matsuura S, Morikawa K, Ito Y, et al. The geriatric nutritional risk index and prognostic nutritional index predict the overall survival of advanced Non-Small cell lung cancer patients. Nutr Cancer. 2022;74(5):1606–1613.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Noma D, Masuda H, et al. Preoperative inflammation-based scores predict early recurrence after lung cancer resection. J Thorac Dis. 2021;13(5):2812–2823.
   PubMed Web of Science ®Google Scholar
• Bacha S, Sghaier A, Habibech S, et al. Advanced lung cancer inflammation index: a prognostic score in patients with metastatic non-small cell lung cancer. Tunis Med. 2017;95(11):976–981.
   PubMedGoogle Scholar
• Ozyurek BA, Ozdemirel TS, Ozden SB, et al. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer? Clin Respir J. 2018;12(6):2013–2019.
   PubMed Web of Science ®Google Scholar
• Shiroyama T, Suzuki H, Tamiya M, et al. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer. Cancer Med. 2018;7(1):13–20.
   PubMed Web of Science ®Google Scholar
• Chantharakhit C, Sujaritvanichpong N. Prognostic impact of the advanced lung cancer inflammation index (ALI) in metastatic Non-Small cell lung cancer treated with first line chemotherapy. Asian Pac J Cancer Prev. 2021;22(4):1149–1156.
   PubMedGoogle Scholar
• Tomita M, Ayabe T, Maeda R, et al. Comparison of Inflammation-Based prognostic scores in patients undergoing curative resection for non-small cell lung cancer. World J Oncol. 2018;9(3):85–90.
   PubMedGoogle Scholar
• Han Z, Hu Z, Zhao Q, et al. The advanced lung cancer inflammation index predicts outcomes of patients with non-small cell lung cancer following video-assisted thoracic surgery. J Int Med Res. 2021;49(12):3000605211062442.
   Web of Science ®Google Scholar
• Mandaliya H, Jones M, Oldmeadow C, et al. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8(6):886–894.
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Karube Y, Inoue T, et al. Advanced lung cancer inflammation index predicts outcomes of patients with pathological stage IA lung adenocarcinoma following surgical resection. Ann Thorac Cardiovasc Surg. 2019;25(2):87–94.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin L, Ji Y, et al. Prognostic value of the advanced lung cancer inflammation index in early-stage non-small cell lung cancer patients undergoing video-assisted thoracoscopic pulmonary resection. Ann Palliat Med. 2020;9(3):721–729.
   PubMed Web of Science ®Google Scholar
• Adachi Y, Tamiya A, Taniguchi Y, et al. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med. 2020;9(4):1383–1391.
   PubMed Web of Science ®Google Scholar
• Lu P, Ma Y, Kai J, et al. A low advanced lung cancer inflammation index predicts a poor prognosis in patients with metastatic Non-Small cell lung cancer. Front Mol Biosci. 2021;8:784667.
   PubMed Web of Science ®Google Scholar
• Palomar-Abril V, Soria-Comes T, Tarazona Campos S, et al. Impact of age on Inflammation-Based scores among patients diagnosed with stage III Non-Small cell lung cancer. Oncology. 2020;98(8):528–533.
   PubMed Web of Science ®Google Scholar
• Mountzios G, Samantas E, Senghas K, et al. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer. ESMO Open. 2021;6(5):100254.
   PubMed Web of Science ®Google Scholar
• Tomita M, Ayabe T, Maeda R, et al. Combination of advanced lung cancer inflammation index and C-Reactive protein is a prognostic factor in patients with operable Non-Small cell lung cancer. World J Oncol. 2017;8(6):175–179.
   PubMedGoogle Scholar
• Oster HS, Dolev Y, Kehat O, et al. Serum hypoalbuminemia is a Long-Term prognostic marker in medical hospitalized patients, irrespective of the underlying disease. JCM. 2022;11(5):1207.
   Google Scholar
• Sproston NR, Ashworth JJ. Role of C-Reactive protein at sites of inflammation and infection. Front Immunol. 2018;9:754.
   PubMed Web of Science ®Google Scholar
• Coffelt SB, Wellenstein MD, de Visser KE. Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016;16(7):431–446.
   PubMed Web of Science ®Google Scholar
• Lee HM, Lee HJ, Chang JE. Inflammatory cytokine: an attractive target for cancer treatment. Biomedicines. 2022;10(9):2116.
   PubMed Web of Science ®Google Scholar
• Sedighzadeh SS, Khoshbin AP, Razi S, et al. A narrative review of tumor-associated macrophages in lung cancer: regulation of macrophage polarization and therapeutic implications. Transl Lung Cancer Res. 2021;10(4):1889–1916.
   PubMed Web of Science ®Google Scholar
• Goubran HA, Stakiw J, Radosevic M, et al. Platelets effects on tumor growth. Semin Oncol. 2014;41(3):359–369.
   PubMed Web of Science ®Google Scholar
• Khairil Anwar NA, Mohd Nazri MN, Murtadha AH, et al. Prognostic prospect of soluble programmed cell death ligand-1 in cancer management. Acta Biochim Biophys Sin (Shanghai). 2021;53(8):961–978.
   PubMed Web of Science ®Google Scholar
• Espana S, Guasch I, Carcereny E. Immunotherapy rechallenge in patients with non-small-cell lung cancer. Pulmonology. 2020;26(4):252–254.
   PubMed Web of Science ®Google Scholar
• Choucair K, Morand S, Stanbery L, et al. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. Cancer Gene Ther. 2020;27(12):841–853.
   PubMed Web of Science ®Google Scholar
• Yucel S, Bilgin B. The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer. J Oncol Pharm Pract. 2021;27(1):71–77.
   PubMed Web of Science ®Google Scholar
• Ohba T, Takamori S, Toyozawa R, et al. Prognostic impact of the controlling nutritional status score in patients with non-small cell lung cancer treated with pembrolizumab. J Thorac Dis. 2019;11(9):3757–3768.
   PubMed Web of Science ®Google Scholar
• Zaitsu J, Yamashita Y, Ishikawa A, et al. Systemic inflammatory score predicts response and prognosis in patients with lung cancer treated with immunotherapy. Anticancer Res. 2021;41(7):3673–3682.
   PubMed Web of Science ®Google Scholar
• Bacha S, Sghaier A, Habibech S, et al. Combined C-reactive protein and neutrophil to lymphocyte ratio use predict survival innon-small-cell lung cancer. Tunis Med. 2017;95(12):229–235.
   PubMedGoogle Scholar
• Mitsuyoshi T, Matsuo Y, Itou H, et al. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy. J Radiat Res. 2018;59(1):50–57.
   PubMed Web of Science ®Google Scholar
• He Y, Gong R, Peng KW, et al. Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer. Biomark Med. 2020;14(9):717–726.
   PubMed Web of Science ®Google Scholar
• Tomita M, Maeda R, Ayabe T, et al. Prognostic impact of a novel tumor marker and inflammation index for patients with non-small-cell lung cancer. Anticancer Res. 2020;40(7):4023–4027.
   PubMed Web of Science ®Google Scholar